Bristol Myers Squibb (CELG-RI) Goodwill & Intangibles (2009 - 2026)

Bristol Myers Squibb (CELG-RI) reported Goodwill & Intangibles of $40.0 billion for Q1 2026, down 9.59% year-over-year from $44.2 billion in Q1 2025, and down 2.14% quarter-over-quarter from $40.9 billion in Q4 2025.

Bristol Myers Squibb (CELG-RI) Goodwill & Intangibles (2009 - 2026) Analysis & Trends

Bristol Myers Squibb (CELG-RI) has 18 years of Goodwill & Intangibles data on file, last reported at $40.0 billion in Q1 2026.

  • Goodwill & Intangibles for Q1 2026 came in at $40.0 billion, down 9.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $40.0 billion (down 9.59% YoY), and the FY2025 annual result was $40.9 billion, down 9.26% from the prior year.
  • Goodwill & Intangibles slipped to $40.0 billion in Q1 2026 per CELG-RI's latest filing, from $40.9 billion in the prior quarter.
  • Over five years, Goodwill & Intangibles peaked at $60.6 billion in Q1 2022 and troughed at $40.0 billion in Q1 2026.
  • A 5-year average of $50.0 billion and a median of $50.1 billion in 2023 frame the typical range for Goodwill & Intangibles.
  • The sharpest annual moves came in 2024 and 2025: Goodwill & Intangibles retreated 0.43% in 2024, then fell 18.85% in 2025.
  • A 5-year view of Goodwill & Intangibles shows it stood at $57.0 billion in 2022, then retreated by 15.38% to $48.2 billion in 2023, then slipped by 6.66% to $45.0 billion in 2024, then slipped by 9.26% to $40.9 billion in 2025, then slipped by 2.14% to $40.0 billion in 2026.
  • Business Quant data shows CELG-RI's Goodwill & Intangibles at $40.0 billion in Q1 2026, $40.9 billion in Q4 2025, and $42.2 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Bristol Myers Squibb - - 8.07 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 39.98 Bn
Dec 31, 2025 40.86 Bn
Sep 30, 2025 42.21 Bn
Jun 30, 2025 43.15 Bn
Mar 31, 2025 44.22 Bn
Dec 31, 2024 45.03 Bn
Sep 30, 2024 48.72 Bn
Jun 30, 2024 51.16 Bn
Mar 31, 2024 54.50 Bn
Dec 31, 2023 48.24 Bn
Sep 30, 2023 50.10 Bn
Jun 30, 2023 52.47 Bn
Mar 31, 2023 54.73 Bn
Dec 31, 2022 57.01 Bn
Sep 30, 2022 59.29 Bn
Jun 30, 2022 58.14 Bn
Mar 31, 2022 60.60 Bn
Dec 31, 2021 63.03 Bn
Sep 30, 2021 65.45 Bn
Jun 30, 2021 68.59 Bn